Skip to content

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

Randomized-Controlled Trial of Acupuncture for Chronic Pain After Breast Cancer Treatment

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02754752
Enrollment
111
Registered
2016-04-28
Start date
2016-09-13
Completion date
2026-12-31
Last updated
2026-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage I Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage III Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7

Brief summary

This randomized phase II trial studies how well electroacupuncture therapy works in reducing chronic pain in patients following surgery for stage I-III breast cancer. Electroacupuncture therapy is a type of complementary integrative medicine in which pulses of weak electrical current are sent through very thin, solid, sterile, stainless steel needles into certain points in the skin. Electroacupuncture therapy may help to lower pain and other surgery-related symptoms.

Detailed description

PRIMARY OBJECTIVE: I. Determine the initial efficacy of electroacupuncture (EA) in reducing chronic pain in women following treatment for breast cancer. SECONDARY OBJECTIVES: I. Determine if EA produces greater improvement in physical functional mobility as compared to sham electroacupuncture (SEA) or waitlist control (WLC)s. II. Determine if EA produces greater improvement in overall quality of life (QOL) and symptoms related to fatigue, sleep and mood disturbance compared to SEA or WLC. III. Determine if EA produces lower pain vigilance and awareness as compared to SEA or WLC. IV. Examine the association between baseline expectancy and outcomes. V. Explore associations between response to acupuncture and biologic measures, including 1) single nucleotide polymorphisms (SNPS) in catechol-O- methyltransferase (COMT) and opioid receptor-mu1 (OPRM1), and 2) autotaxin (ATX)/lysophosphatidic acid (LPA) axis. VI. Explore if EA reduces emotional, financial, and behavioral concerns among patients and caregivers compared to the SEA or WLC. OUTLINE: Patients are randomized to 1 of 3 groups. GROUP I (EA): Patients undergo electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions. GROUP II (SEA): Patients undergo modified electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions. Acupuncture needles are placed in different locations using a different technique than those used for Group I. GROUP III (WLC): Patients receive standard of care without any kind of acupuncture therapy. After completion of study treatment, patients are followed up at 4 weeks.

Interventions

Undergo electroacupuncture therapy

OTHERLaboratory Biomarker Analysis

Correlative studies

OTHERQuality-of-Life Assessment

Ancillary studies

OTHERQuestionnaire Administration

Ancillary studies

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER
Gateway for Cancer Research
CollaboratorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Be adult women \>/= 18 years of age. * Be able to read, write, and speak English * Able to give informed consent * Have a history of stage I, II, or III breast cancer * Have a documented visit with an oncologist during the previous 12-months * Have no current evidence of disease * Have persistent pain (unrelated to aromatase inhibitors or chemotherapy-induced peripheral neuropathy) for at least 3 months following treatment for breast cancer * Have pain severity (arithmetic mean of four pain severity items) \>= 2 on Brief Pain Inventory (BPI) * Have worst pain \>= to 4 (0-10 numeric rating scale \[NRS\]) in the preceding week * Be willing and able to adhere to all study-related procedures * Have completed all cancer treatment (including surgery, chemotherapy and/or radiation) at least 4 months prior to enrollment * Have documented lab work with absolute neutrophil count (ANC) \>= 1.0 K/uL and platelets \>= 50 K/uL in the past 12 months * If applicable, maintain self-management of lymphedema symptoms being performed at home at time of study entry

Exclusion criteria

* Metastatic breast cancer (stage IV) * Known bleeding disorder per patient reported history * Cardiac pacemaker or other implanted electronic devices * New or planned new lymphedema treatment during the study period * Currently receiving or ever received acupuncture for present pain condition * Received acupuncture with electrical stimulation for any condition * Received acupuncture for any condition in the past year

Design outcomes

Primary

MeasureTime frameDescription
Change in pain scores assessed by Brief Pain Inventory (BPI)Baseline to 8 weeksChange in pain scores will be compared between groups. Assessing the initial efficacy of electroacupuncture (EA) relative to sham electroacupuncture (SEA) and waitlist control (WLC), use linear regression and linear mixed model analyses. Pain Scores(0-10) 0 No pain-10 Worst Pain.

Secondary

MeasureTime frameDescription
Presence of single nucleotide polymorphisms (SNPs) in (COMT) catechol-O- methyltransferaseUp to 8 weeksWill explore the correlations between response to acupuncture and presence of different gene variations in (COMT) catechol-O- methyltransferase and (OPRM1). Will use linear regression and linear mixed model analyses.
Presence of single nucleotide polymorphisms (SNPs) in (OPRM1) opioid receptor-mu1Up to 8 weeksWill explore correlations between response to acupuncture and presence of different gene variations in (COMT) catechol-O- methyltransferase and (OPRM1) opioid receptor-mu1. Will use linear regression and linear mixed model analyses.
Change in autotaxin (ATX)/lysophosphatidic acid (LPA) axisBaseline to 8 weeksWill explore correlations between response to acupuncture and ATX-mediated LPA biosynthesis. Will use linear regression and linear mixed model analyses.
Spouse Behavior Subscale of the Multidimensional Pain Inventory (SBS-MPI) QuestionnaireUp to 8 weeksEmotional, financial, and behavioral concerns among patients and caregivers will be compared between (EA) electroacupuncture and (SEA) sham electroacupuncture or (WLC) waitlist control group. (Agree or Disagree 5-1) 1-Strongly Disagree, 2-Disagree, 3-Neither agree or Disagree, 4-Agree 5-Strongly Agree
Caregiver Reaction Assessment (CRA) QuestionnaireUp to 8 weeksEmotional, financial, and behavioral concerns among patients and caregivers will be compared between (EA) electroacupuncture and (SEA) sham electroacupuncture or (WLC) waitlist control group. (Agree or Disagree 5-1) 1-Strongly Disagree, 2-Disagree, 3-Neither agree or Disagree, 4-Agree 5-Strongly Agree
Baseline expectancy of participants will be correlated to the outcomes response.At baselineWill use linear regression and linear mixed model analyses.
Physical functional mobility will be compared.Baseline to 8 weeksChange in physical functional mobility will be compared between groups. Assessing the initial efficacy of (EA) electroacupuncture relative to (SEA) sham electroacupuncture and (WLC) waitlist control group., use linear regression and linear mixed model analyses.
Quality of life (QOL) questionnaireBaseline to 8 weeksChange in overall (QOL) Quality of life will be compared between groups. Assessing the initial efficacy of (EA) electroacupuncture relative to (SEA) sham electroacupuncture and (WLC) waitlist control group., use linear regression and linear mixed model analyses.
Changes in symptoms of fatigue questionnaireBaseline to 8 weeksChanges in symptoms of fatigue, sleep, and mood disturbance will be compared between groups. Assessing the initial efficacy of (EA) electroacupuncture (SEA) sham electroacupuncture and (WLC) waitlist control group., use linear regression and linear mixed mode Fatigue (0-10) 0 No Fatigue-10 Fatigue
Changes in symptoms of sleep questionnaireBaseline to 8 weeksChanges in symptoms of fatigue, sleep, and mood disturbance will be compared between groups. Assessing the initial efficacy of (EA) electroacupuncture (SEA) sham electroacupuncture and (WLC) waitlist control group., use linear regression and linear mixed mode. Thee Pittsburgh Sleep Quality Index (PSQI) Very Good (0) Fairly Good (1) Fairly Bad(2) Very Bad (3)
Changes in symptoms of mood disturbanceBaseline to 8 weeksChanges in symptoms of fatigue, sleep, and mood disturbance will be compared between groups. Assessing the initial efficacy of (EA) electroacupuncture (SEA) sham electroacupuncture and (WLC) waitlist control group., use linear regression and linear mixed mode. Mood (0-10) 0 Does not interfere, 10 Completely Interferes.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLorenzo Cohen

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026